Latest filings (excl ownership)
6-K
Report of Foreign Private Issuer
8 Oct 24
6-K
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation
27 Sep 24
6-K/A
Current report (foreign) (amended)
10 Sep 24
6-K
Report of Foreign Private Issuer
10 Sep 24
6-K
LakeShore Biopharma Announces Leadership Transitions
4 Sep 24
6-K
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024
15 Aug 24
20-F
2024 FY
Annual report (foreign)
15 Aug 24
NT 20-F
Notice of late annual filing (foreign)
31 Jul 24
6-K
Report of Foreign Private Issuer
5 Jul 24
6-K
Report of Foreign Private Issuer
18 Jun 24
6-K
Report of Foreign Private Issuer
10 Jun 24
6-K
YS Biopharma Announces Name Change to LakeShore Biopharma
24 May 24
6-K
YS Biopharma Announces Results of Extraordinary General Meeting
21 May 24
S-8
Registration of securities for employees
20 May 24
424B3
Prospectus supplement
8 May 24
6-K
Report of Foreign Private Issuer
7 May 24
6-K
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
29 Apr 24
6-K
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
19 Apr 24
6-K
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
18 Apr 24
6-K
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
9 Apr 24
6-K
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility
3 Apr 24
6-K
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries
5 Mar 24
6-K
Report of Foreign Private Issuer
23 Feb 24
6-K
Report of Foreign Private Issuer
22 Feb 24
6-K
Report of Foreign Private Issuer
20 Feb 24
6-K
YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting
16 Feb 24
6-K
Report of Foreign Private Issuer
14 Feb 24
6-K
YS Biopharma Announces Appointment of New Directors
14 Feb 24
6-K
Report of Foreign Private Issuer
14 Feb 24
6-K
YS Biopharma Announces US$40 Million Private Placement Financing
9 Feb 24
6-K
Report of Foreign Private Issuer
26 Jan 24
EFFECT
Notice of effectiveness
26 Jan 24
POS AM
Prospectus update (post-effective amendment)
23 Jan 24
6-K
YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024
22 Jan 24
6-K
YS Biopharma Announces Changes to its Board Committees
8 Jan 24
6-K
Report of Foreign Private Issuer
28 Dec 23
6-K
Report of Foreign Private Issuer
20 Dec 23
6-K
Report of Foreign Private Issuer
12 Dec 23
6-K
Report of Foreign Private Issuer
14 Nov 23
424B3
Prospectus supplement
31 Oct 23
Latest ownership filings